

Rolapitant license (continued)



LEERINK SWANN

- Will pay royalties on annual net sales outside of the U.S. and Europe slightly above the single digit percent range
- Will pay royalties until the later of the date that all patent rights licensed from OPKO that cover rolapitant expire and twelve years from the first commercial sale of the product, in each case, on a country-by-country and product-by-product basis.
- In Japan if they out-license to a third party they will share equally with OPKO all amounts received from the license.